MedTrace Logo

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia

NCT04561180 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-07-28

No results posted yet for this study

Summary

To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.

Conditions

Interventions

DRUG

EG-009A

Administered as an Intramuscular injection

DRUG

EG-009A Placebo

Administered as an Intramuscular injection

DRUG

Standard of Care

Standard of Care Treatment for COVID-19 Infection

DRUG

Dexamethasone

The comparator, Administered as an Intravenous infusion

Sponsors & Collaborators

  • Evergreen Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2023-05-01
Completion
2023-05-01
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04561180 on ClinicalTrials.gov